Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluorouracil + leucovorin + oxaliplatin + docetaxel + serplulimab
- Development stage
- Unknown
- Lead developer
- Henlius
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination therapy, often referred to as FLOT-Serplulimab, is a perioperative regimen being evaluated for the treatment of locally advanced gastric adenocarcinoma. It combines the standard-of-care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) with serplulimab, a recombinant humanized anti-PD-1 monoclonal antibody. Serplulimab works by blocking the interaction between PD-1 on T cells and its ligands (PD-L1 and PD-L2), thereby revitalizing the immune system's ability to recognize and destroy tumor cells. The chemotherapy components provide direct cytotoxic effects: docetaxel stabilizes microtubules to inhibit mitosis, oxaliplatin forms DNA cross-links to induce apoptosis, and fluorouracil (potentiated by leucovorin) inhibits thymidylate synthase to disrupt DNA synthesis. This multi-modal approach is designed to maximize pathological complete response (pCR) rates in stage III, PD-L1 positive patients.
- Other names
- FLOT-SerplulimabFLOT plus serplulimab
02
Targets
TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on fluorouracil + leucovorin + oxaliplatin + docetaxel + serplulimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluorouracil + leucovorin + oxaliplatin + docetaxel + serplulimab.